ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice

Molecular Therapy

Volumn 23, Issue 9, 2015, Pages 1434-1443

  Mak, Kai Y ^a   Chin, Ruth ^a   Cunningham, Sharon C ^b   Habib, Miriam R ^c   Torresi, Joseph ^a,d   Sharland, Alexandra F ^c   Alexander, Ian E ^b   Angus, Peter W ^a,d   Herath, Chandana B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; CARBON TETRACHLORIDE; CHOLINE; COLLAGEN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; HYDROXYPROLINE; INTERLEUKIN 6; MESSENGER RNA; METHIONINE; METHOXAMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PARVOVIRUS VECTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA1; ANGIOTENSIN I; AUTACOID; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE;

ADENO ASSOCIATED VIRUS 8; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BLOOD VESSEL TONE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE THERAPY; LIPID PEROXIDATION; LIVER BLOOD VESSEL; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PROMOTER REGION; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TREATMENT OUTCOME; UPREGULATION; VASODILATATION; VIRAL GENE DELIVERY SYSTEM; ADMINISTRATION AND DOSAGE; ANIMAL; ANTIBODY SPECIFICITY; CHEMICALLY INDUCED; CLASSIFICATION; DEPENDOPARVOVIRUS; ENZYME ACTIVATION; GENE VECTOR; GENETICS; HEPATIC STELLATE CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER FUNCTION TEST; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; CYTOKINES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HEPATIC STELLATE CELLS; INFLAMMATION MEDIATORS; INJECTIONS, INTRAPERITONEAL; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MAP KINASE SIGNALING SYSTEM; METHOXAMINE; MICE; NADPH OXIDASE; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SPECIFICITY; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; RNA, MESSENGER;

EID: 84940724584     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.92     Document Type: Article

References (38)

1. Bosetti, C, Levi, F, Lucchini, F, Zatonski, WA, Negri, E and La Vecchia, C (2007). Worldwide mortality from cirrhosis: An update to 2002. J Hepatol 46: 827-839.
2. Schuppan, D and Kim, YO (2013). Evolving therapies for liver fibrosis. J Clin Invest 123: 1887-1901.
3. Bataller, R, Gäbele, E, Parsons, CJ, Morris, T, Yang, L, Schoonhoven, R et al. (2005). Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41: 1046-1055.
4. Bataller, R, Ginès, P, Nicolás, JM, Görbig, MN, Garcia-Ramallo, E, Gasull, X et al. (2000). Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156.
5. Bataller, R, Schwabe, RF, Choi, YH, Yang, L, Paik, YH, Lindquist, J et al. (2003). NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383-1394.
6. Colmenero, J, Bataller, R, Sancho-Bru, P, Domínguez, M, Moreno, M, Forns, X et al. (2009). Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 297: G726-G734.
7. Terui, Y, Saito, T, Watanabe, H, Togashi, H, Kawata, S, Kamada, Y et al. (2002). Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 36(4 Pt 1): 1022.
8. Santos, RA and Ferreira, AJ (2007). Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 16: 122-128.
9. Lubel, JS, Herath, CB, Tchongue, J, Grace, J, Jia, Z, Spencer, K et al. (2009). Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is upregulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci (Lond) 117: 375-386.
10. Osterreicher, CH, Taura, K, De Minicis, S, Seki, E, Penz-Osterreicher, M, Kodama, Y et al. (2009). Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology 50: 929-938.
11. Grace, JA, Klein, S, Herath, CB, Granzow, M, Schierwagen, R, Masing, N et al. (2013). Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 145: 874-884. e5.
12. Herath, CB, Lubel, JS, Jia, Z, Velkoska, E, Casley, D, Brown, L et al. (2009). Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol 297: G98-G106.
13. Herath, CB, Mak, K, Burrell, LM and Angus, PW (2013). Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver. Am J Physiol Gastrointest Liver Physiol 304: G99-108.
14. De Minicis, S and Brenner, DA (2008). Oxidative stress in alcoholic liver disease: role of NADPH oxidase complex. J Gastroenterol Hepatol 23 Suppl 1: S98-103.
15. Paik, YH, Iwaisako, K, Seki, E, Inokuchi, S, Schnabl, B, Osterreicher, CH et al. (2011). The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 53: 1730-1741.
16. Brandes, RP and Kreuzer, J (2005). Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 65: 16-27.
17. Lo, J, Patel, VB, Wang, Z, Levasseur, J, Kaufman, S, Penninger, JM et al. (2013). Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. Exp Physiol 98: 109-122.
18. Poli, G, Biasi, F and Leonarduzzi, G (2008). 4-Hydroxynonenal-protein adducts: A reliable biomarker of lipid oxidation in liver diseases. Mol Aspects Med 29: 67-71.
19. Kyriakis, JM and Avruch, J (1996). Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 18: 567-577.
20. Lemos, VS, Côrtes, SF, Silva, DM, Campagnole-Santos, MJ and Santos, RA (2002). Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats. Br J Pharmacol 135: 1743-1748.
21. Paizis, G, Cooper, ME, Schembri, JM, Tikellis, C, Burrell, LM and Angus, PW (2002). Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123: 1667-1676.
22. Herath, CB, Warner, FJ, Lubel, JS, Dean, RG, Jia, Z, Lew, RA et al. (2007). Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 47: 387-395.
23. Grobe, JL, Mecca, AP, Lingis, M, Shenoy, V, Bolton, TA, Machado, JM et al. (2007). Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292: H736-H742.
24. McCollum, LT, Gallagher, PE and Ann Tallant, E (2012). Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dualspecificity phosphatase 1. Am J Physiol Heart Circ Physiol 302: H801-H810.
25. Wysocki, J, Ortiz-Melo, DI, Mattocks, NK, Xu, K, Prescott, J, Evora, K et al. (2014). ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney. Physiol Rep 2: e00264.
26. Mori, J, Patel, VB, Ramprasath, T, Alrob, OA, DesAulniers, J, Scholey, JW et al. (2014). Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 306: F812-F821.
27. Santos, SH, Andrade, JM, Fernandes, LR, Sinisterra, RD, Sousa, FB, Feltenberger, JD et al. (2013). Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-?B in rats fed with high-fat diet. Peptides 46: 47-52.
28. Su, Z, Zimpelmann, J and Burns, KD (2006). Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69: 2212-2218.
29. Gallagher, PE, Ferrario, CM and Tallant, EA (2008). MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 295: C1169-C1174.
30. Hartleb, M, Moreau, R, Cailmail, S, Gaudin, C and Lebrec, D (1994). Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis. Gastroenterology 107: 1085-1093.
31. Heller, J, Schepke, M, Gehnen, N, Molderings, GJ, Müller, A, Erhard, J et al. (1999). Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 116: 387-393.
32. Hennenberg, M, Biecker, E, Trebicka, J, Jochem, K, Zhou, Q, Schmidt, M et al. (2006). Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 130: 838-854.
33. Hennenberg, M, Trebicka, J, Kohistani, AZ, Heller, J and Sauerbruch, T (2009). Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis. Eur J Clin Invest 39: 906-913.
34. Cunningham, SC, Dane, AP, Spinoulas, A, Logan, GJ and Alexander, IE (2008). Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther 16: 1081-1088.
35. Lu, Y and Song, S (2009). Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci U S A 106: 17158-17162.
36. Dane, AP, Wowro, SJ, Cunningham, SC and Alexander, IE (2013). Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther 20: 460-464.
37. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
38. Goodwin, M, Herath, C, Jia, Z, Leung, C, Coughlan, MT, Forbes, J et al. (2013). Advanced glycation end products augment experimental hepatic fibrosis. J Gastroenterol Hepatol 28: 369-376.